Segment Information (Tables)

9 Months Ended

Sep. 30, 2020

Financial data by reportable segment for the three and nine months ended September 30, 2020 and 2019 is as follows:


	Commercial & Specialty Business		Government Business		IngenioRx		Other		Eliminations		Total
Three Months Ended September 30, 2020
Operating revenue - unaffiliated	$	9,326	$	18,101	$	2,598	$	624	$	—	$	30,649
Operating revenue - affiliated	—		—		2,984		1,174		(4,158)		—
Operating (loss) gain	(234)		246		345		(156)		—		201
Three Months Ended September 30, 2019
Operating revenue - unaffiliated	$	9,284	$	15,955	$	774	$	431	$	—	$	26,444
Operating revenue - affiliated	—		—		1,148		155		(1,303)		—
Operating gain (loss)	924		616		—		(12)		—		1,528
Nine Months Ended September 30, 2020
Operating revenue - unaffiliated	$	27,476	$	52,809	$	7,485	$	1,505	$	—	$	89,275
Operating revenue - affiliated	—		—		8,563		2,772		(11,335)		—
Operating gain (loss)	2,558		2,275		998		(76)		—		5,755
Nine Months Ended September 30, 2019
Operating revenue - unaffiliated	$	28,093	$	46,419	$	880	$	617	$	—	$	76,009
Operating revenue - affiliated	—		—		1,290		1,063		(2,353)		—
Operating gain (loss)	3,505		1,470		—		(74)		—		4,901

Major Product Revenue by Segment

The major product revenues for each of the reportable segments for the three and nine months ended September 30, 2020 and 2019 are as follows:


	Three Months Ended September 30				Nine Months Ended September 30
	2020		2019		2020		2019
Commercial & Specialty Business
Managed care products	$	7,523	$	7,542	$	22,209	$	22,806
Managed care services	1,391		1,330		4,036		4,049
Dental/Vision products and services	318		325		917		975
Other	94		87		314		263
Total Commercial & Specialty Business	9,326		9,284		27,476		28,093
Government Business
Managed care products	17,999		15,847		52,523		46,111
Managed care services	102		108		286		308
Total Government Business	18,101		15,955		52,809		46,419
IngenioRx
Pharmacy products and services	5,582		1,922		16,048		2,170

Total IngenioRx	5,582		1,922		16,048		2,170
Other
Other	1,798		586		4,277		1,680
Eliminations
Eliminations	(4,158)		(1,303)		(11,335)		(2,353)
Total product revenues	$	30,649	$	26,444	$	89,275	$	76,009

Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income

A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three and nine months ended September 30, 2020 and 2019 is as follows:


	Three Months Ended September 30				Nine Months Ended September 30
	2020		2019		2020		2019
Reportable segments’ operating revenue	$	30,649	$	26,444	$	89,275	$	76,009
Net investment income	280		242		591		737
Net realized gains on financial instruments	247		1		241		90
Impairment losses recognized in income	(18)		(13)		(64)		(30)
Total revenues	$	31,158	$	26,674	$	90,043	$	76,806

Reconciliation Of Reportable Segments Operating Gain To Income Before Income Tax Expense Included In The Consolidated Statements Of Income

A reconciliation of reportable segments’ operating gain to income before income tax expense included in our consolidated statements of income for the three and nine months ended September 30, 2020 and 2019 is as follows:


	Three Months Ended September 30				Nine Months Ended September 30
	2020		2019		2020		2019
Reportable segments’ operating gain	$	201	$	1,528	$	5,755	$	4,901
Net investment income	280		242		591		737
Net realized gains on financial instruments	247		1		241		90
Impairment losses recognized in income	(18)		(13)		(64)		(30)
Interest expense	(198)		(185)		(593)		(556)
Amortization of other intangible assets	(93)		(84)		(269)		(256)
(Loss) gain on extinguishment of debt	(30)		—		(34)		1
Income before income tax expense	$	389	$	1,489	$	5,627	$	4,887